1. Litovitz TL, Klein-Schwartz W, Rodgers GC, et al: 2001 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.
Am J Emerg Med 20:391, 2002.
[PubMed: 12216043]
2. Emergency Cardiac Care Committee and Subcommittee, American Heart Association. Part 8-Advanced Challenges in the ECC: Section 2—Toxicology in the ECC. Circulation 108:1223, 2000.
3. Roy TM, Ossorio MA, Cipolla LM, et al: Pulmonary complications after tricyclic antidepressant overdose.
Chest 96:852, 1989.
[PubMed: 2791684]
4. Aldrich T, Morrison J, Cesario T: Aspiration after overdosage of sedative or hypnotic drugs.
South Med J 73:456, 1980.
[PubMed: 7367937]
5. Marik PE: Aspiration pneumonitis and aspiration pneumonia.
N Engl J Med 344:665, 2001.
[PubMed: 11228282]
6. Albertson TE, Dawson A, de Latorre F, et al: Tox-ACLS: Toxicologic oriented advanced cardiac life support. Ann Emerg Med 37:S78, 2001.
7. Mayron R, Ruiz E:
Phenytoin: Does it reverse tricyclic-antidepressant-induced cardiac conduction abnormalities?
Ann Emerg Med 15:876, 1986.
[PubMed: 3740572]
9. Kerns W, Garvey L, Owens J: Cocaine-induced wide complex dysrhythmia.
J Emerg Med 15:321, 1997.
[PubMed: 9258782]
10. Wang RY: pH-dependent cocaine-induced cardiotoxicity.
Am J Emerg Med 17:364, 1999.
[PubMed: 10452435]
11. Beckman KJ, Parker RB, Hariman RJ, et al: Hemodynamic and electrophysiological actions of
cocaine: effects of sodium bicarbonate as an antidote in dogs.
Circulation 83:1799, 1991.
[PubMed: 1850669]
12. Shih RD, Hollander JE, Burstein JL, et al: Clinical safety of
lidocaine in patients with cocaine-associated myocardial infarction.
Ann Emerg Med 26:702, 1995.
[PubMed: 7492040]
14. Southall DR, Kilpatrick SM:
Imipramine poisoning: survival of a child after prolonged cardiac massage.
BMJ 4:508, 1974.
[PubMed: 4434118]
15. Teba L, Schiebel F, Dedhia HV, et al: Beneficial effect of
norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose.
Am J Emerg Med 6:566, 1988.
[PubMed: 3178947]
17. Buchman AL, Dauer J, Geiderman J: The use of vasoactive agents in the treatment of refractory hypotension seen in tricyclic antidepressant overdose.
J Clin Psychopharmacol 10:409, 1990.
[PubMed: 2286710]
18. Ramoska E, Sacchetti AD: Propranolol-induced hypertension in treatment of
cocaine intoxication.
Ann Emerg Med 14:1112, 1985.
[PubMed: 4051280]
19. Hoffman RS, Goldfrank LR: The poisoned patient with altered consciousness: Controversies in the use of a “coma cocktail.”
JAMA 274:562, 1995.
[PubMed: 7629986]
21. Schwartz JA, Koenigsberg MD: Naloxone-induced pulmonary edema.
Ann Emerg Med 16:1294, 1987.
[PubMed: 3662194]
22. Goldfrank LR: The several uses of
naloxone.
Ann Emerg Med 30:105, 1984.
23. Longmire AW, Seger DL: Topics in clinical pharmacology:
Flumazenil, a benzodiazepine antagonist.
Am J Med Sci 306:49, 1993.
[PubMed: 8101045]
24. Mordel A, Winkler E, Almog S, et al: Seizures after
flumazenil administration in a case of combined benzodiazepine and tricyclic antidepressant overdose.
Crit Care Med 20:1733, 1992.
[PubMed: 1458953]
25. Derlet RW, Albertson TE:
Flumazenil induces seizures and death in mixed cocaine-diazepam intoxications.
Ann Emerg Med 23:494, 1994.
[PubMed: 8135424]
26. Weinbroum A, Rudick V, Sorkine P, et al: Use of
flumazenil in the treatment of drug overdose: A double-blind and open clinical study in 110 patients.
Crit Care Med 24:199, 1996.
[PubMed: 8605789]
27. Barnett R, Grace M, Boothe P, et al:
Flumazenil in drug overdose: randomized, placebo-controlled study to assess cost effectiveness.
Crit Care Med 27:10, 1999.
28. Hadad E, Weinbroum AA, Ben-Abraham R: Drug-induced hyperthermia and muscle rigidity: a practical approach.
Eur J Emerg Med 10:149, 2003.
[PubMed: 12789076]
29. Wright N: An assessment of the unreliability of the history given by self-poisoned patients.
Clin Toxicol 16:381, 1980.
[PubMed: 7398227]
30. Olson KR, Pentel PR, Kelley MT: Physical assessment and differential diagnosis of the poisoned patient.
Med Toxicol 2:52, 1987.
[PubMed: 3547006]
31. DuBose TD, Cogan MG, Rector FC: Acid-base disorders, in Brenner BM (ed): Brenner and Rector's The Kidney, 5th ed. Philadelphia, Saunders, 1996, p 1805.
32. Rose BD: Metabolic acidosis, in Rose BD, Post TW (eds): Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed. New York, McGraw-Hill, 2001, p 579.
33. Narins RG, Krishna GG, Yee J, et al: The metabolic acidoses, in Narins RG (ed): Maxwell and Kleeman's Clinical Disorders of Fluid and Electrolyte Metabolism, 5th ed. New York, McGraw-Hill, 1994, p 85.
34. Winter SD, Pearson R, Gabow PA, et al: The fall of the serum anion gap.
Arch Intern Med 150:311, 1990.
[PubMed: 2302006]
35. Oh MS, Carroll HJ: Current concepts: The anion gap.
N Engl J Med 297:814, 1977.
[PubMed: 895822]
36. Gabow PA: Disorders associated with an altered anion gap.
Kidney Int 27:472, 1985.
[PubMed: 2581012]
37. Gabow PA, Clay K, Sullivan JB, et al: Organic acids in ethylene glycol intoxication.
Ann Intern Med 105:16, 1986.
[PubMed: 3717806]
38. Leatherman J, Schmitz PG: Fever, hyperdynamic shock, and multiple-system organ failure. A pseudo-sepsis syndrome associated with chronic salicylate intoxication. Chest 110:1391, 1991.
39. Walker JA, Schwartzbard A, Krauss EA, et al: The missing gap: A pitfall in the diagnosis of
alcohol intoxication by osmometry.
Arch Intern Med 146:1843, 1986.
[PubMed: 3753127]
40. Sweeney TE, Beuchat CA: Limitations of methods of osmometry: Measuring the osmolality of biological fluids. Am J Physiol 264:R469, 1993.
41. Glasser L, Sternglanz PD, Combie J, et al: Serum osmolality and its applicability to drug overdose.
Am J Clin Pathol 60:695, 1973.
[PubMed: 4751712]
42. Glaser DS: Utility of the serum osmolal gap in the diagnosis of methanol or ethylene glycol ingestion.
Ann Emerg Med 27:343, 1996.
[PubMed: 8599495]
44. Hoffman RS, Smilkstein MJ, Howland MA, et al: Osmol gaps revisited: normal values and limitations.
J Toxicol Clin Toxicol 31:81, 1993.
[PubMed: 8433417]
45. Ammar KA, Heckerling PS: Ethylene glycol poisoning with a normal anion gap caused by concurrent ethanol ingestion: importance of the osmolal gap.
Am J Kidney Dis 27:130, 1996.
[PubMed: 8546127]
46. Schelling JR, Howard RL, Winter SD, et al: Increased osmolal gap in alcoholic ketoacidosis and lactic acidosis.
Ann Intern Med 113:580, 1990.
[PubMed: 2400167]
47. Sklar AH, Linas SL: The osmolal gap in renal failure.
Ann Intern Med 98:481, 1983.
[PubMed: 6838071]
48. Tillman DJ, Ruggles DL, Leikin JB: Radiopacity study of extended-release formulations using digitalized radiography.
Am J Emerg Med 12:310, 1994.
[PubMed: 8179737]
49. Brett AS: Implications of discordance between clinical impression and toxicology analysis in drug overdose.
Arch Intern Med 148:437, 1988.
[PubMed: 3341840]
50. Kellerman AL, Fihn SD, LoGerfo JP, Copass MK: Impact of drug screening in suspected overdose. Ann Emerg Med 16:1206, 1987.
52. Mahoney JD, Gross PL, Stern TA, et al: Quantitative serum toxic screening in the management of suspected drug overdose.
Am J Emerg Med. 8:16, 1990.
[PubMed: 2293827]
53. Wigder HN, Erickson T, Morse T, et al: Emergency department poison advice telephone calls.
Ann Emerg Med 25:349, 1995.
[PubMed: 7864475]
54. Merigan KS, Woodard M, Hedges JR, et al: Prospective evaluation of gastric emptying in the self-poisoned patient. Am J Emerg Med 8:479, 1990.
55. Vale JA, Meredith TJ, Proudfoot AT: Syrup of ipecacuanha: Is it really useful?
Br Med J 293:1321, 1986.
[PubMed: 2878703]
56. Vale JA: American Academy of Clinical Toxicology, European Association of Poison Control Centres and Clinical Toxicologists. Position Statement: gastric lavage.
J Toxicol Clin Toxicol 35:711, 1997.
[PubMed: 9482426]
57. Kulig K, Bar-Or D, Cantrill SV, et al: Management of acutely poisoned patients without gastric emptying.
Ann Emerg Med 14:562, 1985.
[PubMed: 2859819]
58. Rudolph JP: Automated gastric lavage and a comparison of 0.9% normal saline solution and tap water irrigant.
Ann Emerg Med 14:1156, 1985.
[PubMed: 3877478]
59. Levy G: Gastrointestinal clearance of drugs with activated charcoal.
N Engl J Med 307:676, 1982.
[PubMed: 7110218]
60. Chyka PA, Seger D: Position Statement: single-dose activated charcoal. American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists.
J Toxicol Clin Toxicol 35:721, 1997.
[PubMed: 9482427]
61. Varga DW, Roy TM, Ossorio MA: Gastric stapling: a significant risk factor in the treatment of tricyclic antidepressant overdose.
J Ky Med Assoc 87:501, 1989.
[PubMed: 2809404]
62. Givens T, Holloway M, Wason S: Pulmonary aspiration of activated charcoal: A complication of its misuse in overdose management.
Pediatr Emerg Care 8:137, 1992.
[PubMed: 1614903]
63. George DL, McLeod R, Weinstein RA: Contaminated commercial charcoal as a source of fungi in the respiratory tract.
Infect Control Hosp Epidemiol 12:732, 1991.
[PubMed: 1813580]
64. Elliott CG, Colby TV, Kelly TM: Charcoal lung. Bronchiolitis obliterans after aspiration of activated charcoal.
Chest 96:672, 1989.
[PubMed: 2766830]
65. Harris CR, Filandrinos D: Accidental administration of activated charcoal into the lung: aspiration by proxy.
Ann Emerg Med 22:1470, 1993.
[PubMed: 8363122]
66. Menzies DG, Busuttil A, Prescott LF: Fatal pulmonary aspiration of oral activated charcoal.
Br Med J 297:459, 1988.
[PubMed: 3139147]
67. Bradberry SM, Vale JA: Multiple-dose activated charcoal: a review of relevant clinical studies.
J Toxicol Clin Toxicol 33:407, 1995.
[PubMed: 7650765]
68. Krenzelok EP, Leikin JB: Approach to a poisoned patient. Dis Mon 42:513, 1996.
69. Vale JA, Krenzelok EP, Barceloux GD, et al: Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 37:731, 1999.
70. Ilkhanipour K, Yealy DM, Krenzelok EP: The comparative efficacy of various multiple-dose activated charcoal regimens.
Am J Emerg Med 10:298, 1992.
[PubMed: 1616516]
71. Keller RE, Schwab RA, Krenzelok EP: Contribution of
sorbitol combined with
AC in prevention of salicylate absorption.
Ann Emerg Med 19:654, 1990.
[PubMed: 2188536]
73. Krenzelok EP, Keller R, Stewart RD: Gastrointestinal transit times of cathartics combined with charcoal.
Ann Emerg Med 14:1152, 1985.
[PubMed: 4061985]
74. Barceloux D, McGuigan M, Hartigan-Go K: Position statement: cathartics. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists.
J Toxicol Clin Toxicol 35:743, 1997.
[PubMed: 9482428]
75. Snodgrass WR, Klaasen CD, Amdur MO, Doull J: Clinical toxicology, in Casarett and Doull's Toxicology: The Basic Science of Poisons, 5th ed. New York, McGraw-Hill, 1995, p 969.
76. Pond SM: Diuresis, dialysis, and hemoperfusion: Indications and benefits.
Emerg Med Clin North Am 2:29, 1984.
[PubMed: 6519021]
77. Pond SM: Principles of techniques used to enhance elimination of toxic compounds, in Goldfrank LR, Flomenbaum NE, Lewin NA, et al (eds): Goldfrank's Toxicologic Emergencies, 5th ed. Norwalk, CT, Appleton & Lange, 1994, p 77.
78. Winchester JF: Active methods for detoxification, in Haddad LM, Winchester JF (eds): Clinical Management of Poisoning and Drug Overdose, 2nd ed. Philadelphia, Saunders, 1990, p 174.
79. Rowland M, Tozer TN: Elimination, in Clinical Pharmacokinetics: Concepts and Applications, 3rd ed. Baltimore, Williams & Wilkins, 1995, p 156.
80. Ismail N, Becker BN: Common poisoning and drug overdose, in Jacobson HR, Striker JE, Klahr S (eds): The Principles and Practice of Nephrology, 2nd ed. St Louis, Mosby, 1995, p 726.
81. Garella S: Extracorporeal techniques in the treatment of exogenous intoxications.
Kidney Int 33:735, 1988.
[PubMed: 3285069]
82. Winchester JF: Use of dialysis and hemoperfusion in treatment of poisoning, in Daugirdas JT, Ing TS (eds): Handbook of Dialysis, 2d ed. Boston, Little, Brown, 1994, p 569.
83. Pond SM: Extracorporeal techniques in the treatment of poisoned patients.
Med J Aust 154:617, 1991.
[PubMed: 2056948]
84. Gwilt PR, Perrier D: Plasma protein binding and distribution characteristics of drugs as indices of the dialyzability.
Clin Pharmacol Ther 24:154, 1978.
[PubMed: 679594]
85. Blye E, Lorch J, Cortell S: Extracorporeal therapy in the treatment of intoxication.
Am J Kid Dis 3:321, 1984.
[PubMed: 6367439]
86. Tilstone WJ, Winchester JF, Reavey PC: Pharmacokinetic concepts. The use of pharmacokinetic principles in determining the effectiveness of removal of toxins from blood.
Clin Pharmacokinet 4:23, 1979.
[PubMed: 369765]
87. Alexander DP, Gambertoglio JG: Drug overdose and pharmacologic considerations in dialysis in Cogan MG, Garovoy MR (eds): Introduction to Dialysis. New York, Churchill Livingston, 1985, p261.
88. Aronoff GR, Brier ME: Prescribing drugs for dialysis patients, in Henrich WL (ed): Principles and Practice of Dialysis, 3rd ed. Philadelphia, Lippincott Williams & Wilkins, 2004, p 147.
89. DeSoi CA, Sahm DF, Umans JG:
Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes.
Am J Kid Dis 20:354, 1992.
[PubMed: 1415203]
90. Touchette MA, Patel RV, Anandan JV, et al:
Vancomycin clearance by high-flux polysulfone hemodialysis membranes in critically ill patients with end-stage renal disease.
Am J Kid Dis 26:469, 1995.
[PubMed: 7645555]
91. Winchester JF, Kriger FL: Hemoperfusion, in Jacobson HR, Striker JE, Klahr S (eds): The Principles and Practice of Nephrology, 2nd ed. St Louis, Mosby, 1995, p 721.
92. Golper TA, Wedel SK, Kaplan AA, et al: Drug removal by continuous arteriovenous hemofiltration: Theory and clinical observations.
Int J Artif Organs 8:307, 1985.
[PubMed: 4077288]
93. Golper TA: Drug removal during continuous renal replacement therapies. Dial Transplant 22:185, 1993.
94. Reetze-Bonorden P, Bohler J, Keller E: Drug dosage in patients during continuous renal replacement therapy: Pharmacokinetic and therapeutic considerations.
Clin Pharmacokinet 24:362, 1993.
[PubMed: 8504621]
95. Bellomo R, Kearly Y, Parkin G, et al: Treatment of life-threatening
lithium toxicity with continuous arterio-venous hemodiafiltration.
Crit Care Med 19:836, 1991.
[PubMed: 2055063]
96. Leblanc M, Raymond M, Bonnardeaux A, et al:
Lithium poisoning treated by high-performance continuous arteriovenous and venovenous hemodiafiltration.
Am J Kid Dis 27:365, 1996.
[PubMed: 8604705]
97. Collee GG, Hanson GC: The management of acute poisoning.
Br J Anesth 70:562, 1993.
[PubMed: 8318332]
98. Brett AS, Rothschild N, Gray R, et al: Predicting the clinical course of intentional drug overdose: Implications for the use of the intensive care unit.
Arch Intern Med 147:133, 1987.
[PubMed: 3800515]
99. Kulling P, Persson H: The role of the intensive care unit in the management of the poisoned patient.
Med Toxicol 1:375, 1986.
[PubMed: 3537625]
100. Hamad AE: Predicting the need for medical intensive care monitoring in drug-overdosed patients. J Intensive Care 15:321, 2000.
101. Callaham M: Admission criteria for tricyclic antidepressant ingestion.
West J Med 137:425, 1982.
[PubMed: 7179959]
103. McBride PV, Rumack BH:
Acetaminophen intoxication.
Semin Dial 5:292, 1992.
104. Corcoran GB, Mitchell JR, Vaishnav YN, et al: Evidence that
acetaminophen and
N-hydroxyacetaminophen form a common arylating intermediate,
N-acetyl-
p-benzoquinoneimine.
Mol Pharmacol 18:536, 1980.
[PubMed: 7464816]
107. Bond GR, Lite LK: Population-based incidence and outcome of
acetaminophen poisoning by type of ingestion.
Acad Emerg Med 6:1115, 1999.
[PubMed: 10569383]
108. Buckley NA, Whyte IM, O'Connell DL, et al: Activated charcoal reduces the need for N-acetylcysteine treatment after
acetaminophen (paracetamol) overdose.
J Toxicol Clin Toxicol 37:753, 1999.
[PubMed: 10584587]
109. Smilkstein MJ, Knapp GL, Kulig KW, et al: Efficacy of oral
n-acetylcysteine in the treatment of
acetaminophen overdose. Analysis of the national multicenter study (1976–1985).
N Engl J Med 319:1557, 1988.
[PubMed: 3059186]
110. Keays R, Harrison PM, Wendon JA, et al: Intravenous
acetylcysteine in paracetamol-induced fulminant hepatic failure: A prospective controlled trial.
Br Med J 303:1026, 1991.
[PubMed: 1954453]
111. Harrison PM et al: Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of
acetylcysteine.
Lancet 335:1572, 1990.
[PubMed: 1972496]
112. Harrison PM et al: Improvement by N-acetylcysteine of hemodynamics and
oxygen transport in fulminant hepatic failure.
N Engl J Med 324:1852, 1991.
[PubMed: 1904133]
114. Prescott LF, Illingworth RN, Critchley JA, et al: Intravenous N-acetylcysteine: The treatment of choice for paracetamol poisoning.
BMJ 2:1097, 1979.
[PubMed: 519312]
115. Smilkstein MJ, Bronstein
AC, Linden C, et al:
Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol.
Ann Emerg Med 20:1058, 1991.
[PubMed: 1928874]
116. Mutimer DJ, Ayres RC, Neuberger JM, et al: Serious paracetamol poisoning and the results of liver transplantation.
Gut 35:809, 1994.
[PubMed: 8020810]
117. O'Grady JG, Alexander GJ, Hayllar KM, et al: Early indicators of prognosis in fulminant hepatic failure.
Gastroenterology 97:439, 1989.
[PubMed: 16550536]
118. Mitchell I, Bihari D, Chang R, et al: Earlier identification of patients at risk from acetaminophen-induced acute liver failure.
Crit Care Med 26:279, 1998.
[PubMed: 9468165]
119. Ammar KA, Heckerling PS: Ethylene glycol poisoning with a normal anion gap caused by concurrent ethanol ingestion: Importance of the osmolal gap.
Am J Kid Dis 27:130, 1996.
[PubMed: 8546127]
120. Walker JA, Schwartzbard A, Krauss EA, et al: The missing gap: a pitfall in the diagnosis of
alcohol intoxication by osmometry.
Arch Intern Med 146:1843, 1986.
[PubMed: 3753127]
121. Halperin ML, Goldstein MB: Metabolic acidosis, in Halperin ML, Goldstein MB (eds): Fluid, Electrolyte, and Acid-Base Physiology: A Problem-Based Approach, 2nd ed. Philadelphia, Saunders, 1994, p 67.
122. Jacobsen D, McMartin KE: Antidotes for methanol and ethylene glycol poisoning.
Clin Toxicol 35:127, 1997.
[PubMed: 9120880]
123. Gabow PA: Ethylene glycol intoxication.
Am J Kid Dis 11:277, 1988.
[PubMed: 3344748]
124. Wine H, Savitt D, Abuelo JG: Ethylene glycol intoxication. Semin Dial 7:338, 1994.
125. Palmer BF, Eigenbrodt EH, Henrich WL: Cranial nerve deficit: A clue to the diagnosis of ethylene glycol poisoning.
Am J Med 87:91, 1989.
[PubMed: 2741987]
126. Mallya KB, Mendis T, Guberman A: Bilateral facial paralysis following ethylene glycol toxicity.
Can J Neurol Sci 13:340, 1986.
[PubMed: 3779535]
127. Gabow PA: Ethylene glycol intoxication.
Am J Kid Dis 11:277, 1988.
[PubMed: 3344748]
128. Wine H, Savitt D, Abuelo JG: Ethylene glycol intoxication. Semin Dial 7:338, 1994.
129. Kruse JA: Methanol poisoning.
Intensive Care Med 18:391, 1992.
[PubMed: 1469176]
130. Hantson P, Mahieu P: Pancreatic injury following acute methanol poisoning.
J Toxicol Clin Toxicol 38:297, 2000.
[PubMed: 10866330]
131. Brent J: Current management of ethylene glycol poisoning.
Drugs 61:979, 2001.
[PubMed: 11434452]
132. Brent J, McMartin K, Phillips S, et al:
Fomepizole for the treatment of ethylene glycol poisoning.
N Engl J Med 340:832, 1999.
[PubMed: 10080845]
133. Brent J, McMartin K, Phillips S, et al:
Fomepizole for the treatment of methanol poisoning.
N Engl J Med 344:424, 2001.
[PubMed: 11172179]
134. McCoy HG, Cipolle RJ, Ehlers SM, et al: Severe methanol poisoning: application of a pharmacokinetic model for ethanol therapy and hemodialysis.
Am J Med 67:804, 1979.
[PubMed: 507092]
135. Lacouture PG, Wason S, Abrams A, Lovejoy FH: Acute isopropyl
alcohol intoxication: Diagnosis and management.
Am J Med 75:680, 1983.
[PubMed: 6624775]
136. Parry MF, Wallach R: Ethylene glycol poisoning.
Am J Med 57:143, 1974.
[PubMed: 4834513]
137. Peterson CD, Collins AJ, Himes JM, et al: Ethylene glycol poisoning: pharmacokinetics during therapy with ethanol and hemodialysis.
N Engl J Med 304:21, 1981.
[PubMed: 7432434]
138. Baud FJ, Gaillot M, Astier A, et al: Treatment of ethylene glycol poisoning with intravenous 4-methylpyrazole.
N Engl J Med 319:97, 1988.
[PubMed: 3380132]
139. Rosansky SJ: Isopropyl
alcohol poisoning treated with hemodialysis: kinetics of isopropyl
alcohol and acetone removal.
J Toxicol Clin Toxicol 19:265, 1982.
[PubMed: 7131613]
140. Sabeel AI, Kurkus J, Lindholm T: Intensified dialysis treatment of ethylene glycol intoxication.
Scand J Urol Nephrol 29:125, 1995.
[PubMed: 7569787]
142. Jones AL, Simpson KJ: Mechanisms and management of hepatotoxicity in ecstasy (MDMA) and
amphetamine intoxications.
Aliment Pharmacol Ther 12:129, 1999.
145. Sutherland GR, Park J, Proudfoot AT: Ventilation and acid-base changes in deep coma due to barbiturate or tricyclic antidepressant poisoning.
Clin Toxicol 11:403, 1977.
[PubMed: 589953]
146. Raymond LW: “Barbiturate blisters” in a case of severe hypoglycaemic coma.
Lancet 2:764, 1972.
[PubMed: 4116178]
147. Boldy DA, Vale JA, Prescott LF: Treatment of phenobarbitone poisoning with repeated oral administration of activated charcoal.
Q J Med 61:997, 1986.
[PubMed: 3659250]
149. Berg MJ, Berlinger WG, Goldberg MJ, et al: Acceleration of the body clearance of
phenobarbital by oral activated charcoal.
N Engl J Med 307:642, 1982.
[PubMed: 7050705]
150. Pond SM, Olson KR, Osterloh JD, et al: Randomized study of the treatment of
phenobarbital overdose with repeated doses of activated charcoal.
JAMA 251:3104, 1984.
[PubMed: 6726981]
151. Vale JA, Krenzelok EP, Barceloux GD, et al: Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 37:731, 1999.
152. Linton AL, Luke RG, Briggs JD: Methods of forced diuresis and its application in barbiturate poisoning.
Lancet 2:377, 1967.
[PubMed: 4166328]
154. Lorch JA, Garella S: Hemoperfusion to treat intoxications.
Ann Intern Med 91:301, 1979.
[PubMed: 111596]
156. Jacobsen D, Wiik-Larsen E, Dahl T, et al: Pharmacokinetic evaluation of haemoperfusion in
phenobarbital poisoning.
Eur J Clin Pharmacol 26:109, 1984.
[PubMed: 6714282]
157. Bouget J, Breurec JY, Baert A, et al: Value of charcoal by oral route in patients admitted to emergency department for voluntary absorption of benzodiazepines (French).
J Toxicol Clin Exp 9:287, 1989.
[PubMed: 2625677]
159. Shalansky SJ, Naumann TL, Englander FA: Effect of
flumazenil on benzodiazepine-induced respiratory depression.
Clin Pharmacol 12:483, 1993.
[PubMed: 8354035]
160. The
Flumazenil in Benzodiazepine Intoxication Multicenter Study Group: Treatment of benzodiazepine overdose with
flumazenil.
Clin Ther 14:978, 1992.
161. Spivey WH, Roberts JR, Derlet RW: A clinical trial of escalating doses of
flumazenil for reversal of suspected benzodiazepine overdose in the emergency department.
Ann Emerg Med 22:1813, 1993.
[PubMed: 8239101]
162. Weinbroum A, Halpern P, Geller E: The use of
flumazenil in the management of acute drug poisoning—a review.
Intensive Care Med 17(Suppl 1):S32, 1991.
163. Hoffman EJ, Warren EW:
Flumazenil: A benzodiazepine antagonist.
Clin Pharmacol 12:641; quiz 699, 1993.
165. Agmo A, Galvan A, Heredia A, et al:
Naloxone blocks the antianxiety but not the motor effects of benzodiazepines and
pentobarbital: Experimental studies and literature.
Psychopharmacology 120:186, 1995.
[PubMed: 7480551]
166. Forster A, Morel D, Bachmann M, et al: Respiratory depressant effects of different doses of
midazolam and lack of reversal with naloxone—a double-blind randomized study.
Anesth Analg 62:920, 1983.
[PubMed: 6137171]
167. Love JN: Beta-blocker toxicity: a clinical diagnosis.
Am J Emerg Med 12:356, 1994.
[PubMed: 8179751]
168. Love JN, Howell JM, Litovitz TL, et al: Acute beta blocker overdose: factors associated with the development of cardiovascular morbidity.
J Toxicol Clin Toxicol 38:275, 2000.
[PubMed: 10866327]
169. Love JN: Beta blocker toxicity after overdose: when do symptoms develop in adults?
J Emerg Med 12:799, 1994.
[PubMed: 7884199]
170. Reith DM, Dawson AH, Epid D, et al: Relative toxicity of beta blockers in overdose.
J Toxicol Clin Toxicol 34:273, 1996.
[PubMed: 8667464]
171. Love JN, Litovitz TL, Howell JM, et al: Characterization of fatal beta blocker ingestion. A review of the American Association of Poison Control Centers data from 1985 to 1995.
J Toxicol Clin Toxicol 35:353, 1997.
[PubMed: 9204094]
172. Lipski JL, Kaminsky D, Donoso E, et al: Electrophysiological effects of
glucagon on the normal canine heart.
Am J Physiol 222:1107, 1972.
[PubMed: 4336711]
173. Love JN, Sachdeva DK, Bessman ES, et al: A potential role for
glucagon in the treatment of drug-induced symptomatic bradycardia.
Chest 114:323, 1998.
[PubMed: 9674488]
174. Kerns W, Schroeder D, Williams C, et al.
Insulin improves survival in a canine model of acute beta-blocker toxicity.
Ann Emerg Med 29:748, 1997.
[PubMed: 9174520]
175. Kerns W, Kline J, Ford MD: Beta-blocker and calcium channel blocker toxicity.
Emerg Med Clin North Am 12:365, 1994.
[PubMed: 7910555]
176. Buckley NA, Dawson AH, Howarth DM, et al: Slow release
verapamil poisoning: Use of polyethylene glycol whole-bowel lavage and high-dose calcium.
Med J Aust 158:202, 1993.
[PubMed: 8450791]
178. Kenny J: Treating overdose with calcium channel blockers.
BMJ 308:992, 1994.
[PubMed: 8167534]
179. Luscher TF, Noll G, Sturmer T, et al: Calcium gluconate in severe
verapamil intoxication.
N Engl J Med 330:718, 1994.
[PubMed: 8107735]
181. Yuan TH, Kerns WP, Tomaszewski CA, et al: Insulin-glucose as adjunctive therapy for severe calcium channel antagonist poisoning.
J Toxicol Clin Toxicol 37:463, 1999.
[PubMed: 10465243]
182. Boyer EW, Shannon M: Treatment of calcium-channel blocker intoxication with
insulin infusion.
N Engl J Med 344:1721, 2001.
[PubMed: 11386285]
183. Cobb N, Etzel RA. Unintentional carbon monoxide-related deaths in the United States, 1979 through 1988.
JAMA 266:659, 1991.
[PubMed: 1712865]
184. Wittenberg BA, Wittenberg JB: Effects of carbon monoxide on isolated heart muscle cells. Res Rep Health Eff Inst 62:1, 13, 1993.
185. Taitelman U, Schmidt GA: Inhaled toxins, in Hall JB, Schmidt GA, Wood LDH (eds): Principles of Critical Care. New York, McGraw-Hill, 1992, p 2117.
186. Dahms TE, Younis LT, Wiens RD, et al: Effects of carbon monoxide exposure in patients with documented cardiac arrhythmias.
J Am Coll Cardiol 21:442, 1993.
[PubMed: 7678844]
187. Birky MM, Clarke FB: Inhalation of toxic products from fires.
Bull N Y Acad Med 57:997, 1981.
[PubMed: 6274458]
188. Sawa GM, Watson CPM, Terbrugge K, et al: Delayed encephalopathy following carbon monoxide intoxication.
Can J Neurol Sci 8:77, 1981.
[PubMed: 7225962]
189. Choi IS: Delayed neurologic sequelae in carbon monoxide intoxication.
Arch Neurol 40:433, 1983.
[PubMed: 6860181]
190. Tom T, Abedon S, Clark RI, et al: Neuroimaging characteristics in carbon monoxide toxicity.
J Neuroimaging 6:161, 1996.
[PubMed: 8704291]
191. Buckley RG, Aks SE, Eshom JL, et al: The pulse oximetry gap in carbon monoxide intoxication.
Ann Emerg Med 24:252, 1994.
[PubMed: 8037391]
192. Touger M, Gallagher EJ, Tyrell J: Relationship between venous and arterial carboxyhemoglobin levels in patients with suspected carbon monoxide poisoning.
Ann Emerg Med 25:481, 1995.
[PubMed: 7710152]
193. Takeuchi A, Vesely A, Rucker J, et al: A simple “new” method to accelerate clearance of carbon monoxide.
Am J Resp Crit Care Med 161:1816, 2000.
[PubMed: 10852750]
194. Tibbles PM, Edelsberg JS: Hyperbaric-oxygen therapy.
N Engl J Med 334:1642, 1996.
[PubMed: 8628361]
195. Tibbles PM, Perrotta PL: Treatment of carbon monoxide poisoning: A critical review of human outcome studies comparing normobaric
oxygen with hyperbaric
oxygen.
Ann Emerg Med 24:269, 1994.
[PubMed: 8037395]
196. Raphael JC, Elkharrat D, Jars-Guincestre MC, et al: Trial of normobaric and hyperbaric
oxygen for acute carbon monoxide intoxication.
Lancet 2:414, 1989.
[PubMed: 2569600]
197. Thom SR, Taber RL, Mendiguren II, et al: Delayed neuropsychologic sequelae after carbon monoxide poisoning: prevention by treatment with hyperbaric
oxygen.
Ann Emerg Med 25:474, 1995.
[PubMed: 7710151]
198. Ducasse JL, Celsis P, Marc-Vergnes JP: Non-comatose patients with acute carbon monoxide poisoning: Hyperbaric or normobaric oxygenation?
Undersea Hyperb Med 22:9, 1995.
[PubMed: 7742714]
199. Weaver LK, Hopkins RO, Larson-Lohr V: Neuropsychologic and functional recovery from severe carbon monoxide poisoning without hyperbaric
oxygen therapy.
Ann Emerg Med 27:736, 1996.
[PubMed: 8644961]
200. Weaver LK, Hopkins RO, Chan KJ, et al: Hyperbaric
oxygen for acute carbon monoxide poisoning.
N Engl J Med 347:1057, 2002.
[PubMed: 12362006]
201. Shimada H, Morita T, Kunimoto F, et al: Immediate application of hyperbaric
oxygen therapy using a newly devised transportable chamber.
Am J Emerg Med 14:412, 1996.
[PubMed: 8768169]
202. Gorman DF, Clayton D, Gilligan JE, et al: A longitudinal study of 100 consecutive admissions for carbon monoxide poisoning to the Royal Adelaide Hospital.
Anaesth Intensive Care 20:311, 1992.
[PubMed: 1524170]
203. Raphael J-C, Elkharrat D, Jars-Guincestre M-C, et al: Trial of normobaric and hyperbaric
oxygen for acute carbon monoxide intoxication.
Lancet 1:1414, 1989.
204. Cregler LL, Mark H: Medical complications of
cocaine abuse.
N Engl J Med 317:1495, 1986.
205. Wilson LD, Henning RJ, Suttheimer C, et al: Cocaethylene causes dose-dependent reductions in cardiac function in anesthetized dogs.
J Cardiovasc Pharmacol 26:965, 1995.
[PubMed: 8606535]
206. Reeves RR, McWilliams ME, Fitz-Gerald M: Cocaine-induced ischemic cerebral infarction mistaken for a psychiatric syndrome.
South Med J 88:352, 1995.
[PubMed: 7886536]
207. Nolte KB, Brass LM, Fletterick CF: Intracranial hemorrhage associated with
cocaine abuse: a prospective autopsy study.
Neurology 46:1291, 1996.
[PubMed: 8628469]
208. Daras M, Tuchman AJ, Koppel BS, et al: Neurovascular complications of
cocaine.
Acta Neurol Scand 90:124, 1994.
[PubMed: 7801738]
209. Martin K, Rogers T, Kavanaugh A: Central nervous system angiopathy associated with
cocaine abuse.
J Rheumatol 22:780, 1995.
[PubMed: 7791183]
210. Lalouschek W, Schnider P, Aull S, et al:
Cocaine abuse—with special reference to cerebrovascular complications (German).
Wiener Klinische Wochenschrift 107:516, 1995.
[PubMed: 7483634]
211. Chang RA, Rossi NF: Intermittent
cocaine use associated with recurrent dissection of the thoracic and abdominal aorta.
Chest 108:1758, 1995.
[PubMed: 7497801]
212. Willens HJ, Chakko SC, Kessler KM: Cardiovascular manifestations of
cocaine abuse. A case of recurrent dilated cardiomyopathy.
Chest 106:594, 1994.
[PubMed: 7774343]
213. Billman GE:
Cocaine: A review of its toxic actions on cardiac function.
Crit Rev Toxicol 25:113, 1995.
[PubMed: 7612173]
217. Hollander JE, Hoffman RS, Gennis P, et al: Prospective multicenter evaluation of cocaine-associated chest pain.
Cocaine Associated Chest Pain (COCHPA) Study Group.
Acad Emerg Med 1:330, 1994.
[PubMed: 7614278]
218. Trabulsy ME:
Cocaine washed out syndrome in a patient with acute myocardial infarction.
Am J Emerg Med 13:538, 1995.
[PubMed: 7662059]
219. Hollander JE, Hoffman RS, Gennis P, et al: Cocaine-associated chest pain: One-year follow-up.
Acad Emerg Med 2:179, 1995.
[PubMed: 7497030]
220. Averbach M, Casey KK, Frank E: Near-fatal status asthmaticus induced by nasal insufflation of
cocaine.
South Med J 89:340, 1996.
[PubMed: 8604469]
221. Silverman RS, Lee-Chiong TL Jr, Sherter CB: Stridor from edema of the arytenoids, epiglottis, and vocal cords after use of free-base
cocaine.
Chest 108:1477, 1995.
[PubMed: 7587472]
222. Yakel DL Jr, Eisenberg MJ: Pulmonary artery hypertension in chronic intravenous
cocaine users.
Am Heart J 130:398, 1995.
[PubMed: 7631626]
223. Albertson TE, Walby WF, Derlet RW: Stimulant-induced pulmonary toxicity.
Chest 108:1140, 1995.
[PubMed: 7555128]
224. Forrester JM, Steele AW, Waldron JA, et al: Crack lung: An acute pulmonary syndrome with a spectrum of clinical and histopathologic findings.
Am Rev Resp Dis 142:462, 1990.
[PubMed: 2382909]
225. Daras M, Kakkouras L, Tuchman AJ, et al: Rhabdomyolysis and hyperthermia after
cocaine abuse: A variant of the neuroleptic malignant syndrome?
Acta Neurolog Scand 92:161, 1995.
[PubMed: 7484066]
226. Roth D, Alarcon FJ, Fernandez JA, et al: Acute rhabdomyolysis associated with
cocaine intoxication.
N Engl J Med 319:673, 1988.
[PubMed: 3412385]
227. Daras M, Kakkouras L, Tuchman AJ, et al: Rhabdomyolysis and hyperthermia after
cocaine abuse: A variant of the neuroleptic malignant syndrome?
Acta Neurol Scand 92:161, 1995.
[PubMed: 7484066]
228. Sanjuanbenito Dehesa A, Fernandez Cebrian JM: Ischaemic colitis induced by
cocaine abuse.
Br J Surg 82:138, 1995.
229. Goodman PE, Rennie WP: Renal infarction secondary to nasal insufflation of
cocaine.
Am J Emerg Med 13:421, 1995.
[PubMed: 7605528]
230. Kudrow DB, Henry DA, Haake DA, et al: Botulism associated with
Clostridium botulinum sinusitis after intranasal
cocaine abuse.
Ann Intern Med 109:984, 1988.
[PubMed: 3057986]
231. MacDonald KL, Rutherford GW, Friedman SM, et al: Botulism and botulism-like illness in chronic drug abusers.
Ann Intern Med 102:616, 1985.
[PubMed: 3985512]
232. Marzuk PM, Tardiff K, Leon
AC, et al: Fatal injuries after
cocaine use as a leading cause of death among young adults in New York City.
N Engl J Med 332:1753, 1995.
[PubMed: 7760893]
233. Hoffman RS, Smilkstein MJ, Goldfrank LR: Whole bowel irrigation and the
cocaine body-packer: A new approach to a common problem.
Am J Emerg Med 8:523, 1990.
[PubMed: 2222597]
234. Hierholzer J, Cordes M, Tantow H, et al: Drug smuggling by ingested cocaine-filled packages: conventional x-ray and ultrasound.
Abdominal Imaging 20:333, 1995.
[PubMed: 7549738]
235. Makosiej FJ, Hoffman RS, Howland MA, et al: An in vitro evaluation of
cocaine hydrochloride adsorption by activated charcoal and desorption upon addition of polyethylene glycol electrolyte lavage solution.
J Toxicol Clin Toxicol 31:381, 1993.
[PubMed: 8355315]
236. Glass JM, Scott HJ: “Surgical mules”: The smuggling of drugs in the gastrointestinal tract.
J Roy Soc Med 88:450, 1995.
[PubMed: 7562828]
237. Catravas JD, Waters IW: Acute
cocaine intoxication in the conscious dog: studies on the mechanism of lethality.
J Pharmacol Exp Ther 217:350, 1981.
[PubMed: 7229977]
238. Thiebot MH, Kloczko J, Chermat R, et al: Enhancement of cocaine-induced hyperactivity in mice by benzodiazepines: Evidence for an interaction of GABAergic processes with catecholaminergic neurons?
Eur J Pharmacol 76:335, 1981.
[PubMed: 6276192]
239. Brogan WC 3rd, Lange RA, Kim AS, et al: Alleviation of cocaine-induced coronary vasoconstriction by
nitroglycerin.
J Am Coll Cardiol 18:581, 1991.
[PubMed: 1906905]
240. Hollander JE: The management of cocaine-associated myocardial ischemia.
N Engl J Med 333:1267, 1995.
[PubMed: 7566005]
241. Hollander JE, Carter